(MedPage Today) — The effects of the JAK inhibitor baricitinib (Olumiant) waned after treatment was stopped among patients with new-onset type 1 diabetes, 2-year data from the phase II BANDIT trial showed.
After treatment was stopped, C-peptide…
Source link : https://www.medpagetoday.com/meetingcoverage/easd/117538
Author :
Publish date : 2025-09-18 22:01:00
Copyright for syndicated content belongs to the linked Source.
